Accelerate Diagnostics Inc. (NASDAQ:AXDX) does about 508.82K shares in volume on a normal day but saw 313207 shares change hands in Monday trading. The company now has a market cap of 895.50M USD and an enterprise value of about $965.43M. Its current market price is $16.27, marking a decrease of -2.34% compared to the previous close of $16.66. The 52 week high reached by this stock is $22.13 whilst the lowest price level in 52 weeks is $4.53. The script in recent trading has seen the stock touch a high of $16.97 and a low of $16.07.
Accelerate Diagnostics Inc. (AXDX) has a 20-day trading average at $14.08 and the current price is -26.48% off the 52-week high compared with 259.16% distance from its 52-week low. The 50-day simple moving average of the closing price is $11.15 and its 200-day simple moving average is $13.70. If we look at the stock’s price movements over the week, volatility stands at 8.60%, which increases to 10.31% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 65.43 to suggest the stock is neutral.
4 analysts observing the Accelerate Diagnostics Inc. (AXDX) stock have set the 12-month price targets for the company’s shares at between $12.00 and $14.00. The consensus objective for the share price is $13.50, suggesting that the stock has a potential downside of -20.52% over the period. The median price target is -25.15% away from the current levels at $13.00.
FactSet Research has provided data showing that 4 brokerages have issued ratings for the stock. 1 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Hold and Wall Street’s advice is for investors to Moderate Buy the stock.
JP Morgan also downgraded the stock to “Neutral” from Overweight on November 07, 2018 at a price target of . Craig Hallum initiated its price target at $25.
The current price level is 18.50%, 47.40%, and 18.58% away from its SMA20, SMA50, and SMA200 respectively, with the AXDX price moving below the 50-day SMA on July 13. Accelerate Diagnostics Inc. (AXDX) stock is up 1.50% over the week and 77.43% over the past month. Its price is -3.73% year-to-date and -14.59% over the past year.
The stock last released its quarterly earnings report for quarter ended 3/30/2020, with the company’s earnings per share (EPS) of -$0.39 below consensus estimates by -$0.01. The company’s next earnings report is expected on 08/10/2020, with forecasts estimating quarterly EPS at -$0.34 and -$1.41 for whole year. AXDX’s earnings per share are forecast to grow by 9.00% this year and 22.00% over next year. Expected sales for next quarter are $3.58 million, which analysts say will come at $13.37 million for the current fiscal year and next year at $34.87 million. In addition, estimates put the company’s current quarterly revenue at an average of $2.46 million.
Its 12-month price target is $13.00. To reach the target analysts have set, the stock logically needs to shrink -20.52 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $12.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $14.00.
Outstanding shares total 54.84M with insiders holding 40.66% of the shares and institutional holders owning 53.53% of the company’s common stock. The company has a return on investment of -59.30%. The beta has a value of 2.91. Price to sales ratio is 90.45.
According to a U.S. Securities and Exchange Commission filing, CS Invt Fds 2 – (Lux) Robotics has reduced its position in Accelerate Diagnostics Inc. (AXDX) to 1,586,390 shares, mirroring a recent drop by -33.90%. CS Invt Fds 2 – (Lux) Robotics dumped -0.81 million shares of Accelerate Diagnostics Inc. common stock bringing its total worth to about $13.25 million at the end of recent close, SEC documents show. CS Invt Fds 2 – (Lux) Robotics isn’t the only investment manager who changed stakes and is followed by CS Invt Fds 2 – (Lux) Digital H, which sold off 0.0 shares to end up with 1,100,000 shares worth $9.19 million.